ACHN: Summary for Achillion Pharmaceuticals, Inc. - Yahoo! Singapore Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:18pm SGT - The Singapore stock market is closed.

To create a watchlist or portfolio of shares, Register

FINANCE HOME PAGE

INVESTING

FINANCE NEWS

Achillion Pharmaceuticals, Inc. (ACHN)

At 5:00AM SGT: 2.37 USD 0.00 (0.00%)

MORE ON ACHN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Achillion Pharmaceuticals, Inc. (NGM:ACHN) Delayed quote data

Last Trade:	2.37 USD
Trade Time:	5:00AM SGT
Change:	0.00 (0.00%)
Prev Close:	2.37
Open:	N/A
Bid:	2.11 x 400
Ask:	3.20 x 600
1y Target Est:	6.40

Day's Range:	N/A - N/A
52wk Range:	1.10 - 3.89
Volume:	0
Avg Vol (3m):	706,902
Market Cap:	63.17M
P/E (ttm):	N/A
EPS (ttm):	-1.05
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Use Y! Toolbar to track stocks

Add ACHN to Portfolio

Download Data

HEADLINES

•	Achillion to Present at 12th Annual BIO CEO and Investor Conference
	GlobeNewswire (Tue 5:00am)

•	China Biotech Week in Review: New Investments in Life Science
	at Seeking Alpha (Mon, Feb 8)

•	Achillion Pharma Out-Licensed China Rights for HIV, Hepatitis Treatment
	at Seeking Alpha (Thu, Feb 4)

•	ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Thu, Feb 4)

•	Ann Taylor, Lexmark, Achillion Pharma big movers
	AP (Wed, Feb 3)

•	Achillion Announces Closing of Underwriters' Over-Allotment Option
	GlobeNewswire (Wed, Feb 3)

•	Movers roundup: Rudolph Technologies, Hologic
	AP (Wed, Feb 3)

•	ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
	EDGAR Online (Wed, Feb 3)

•	Achillion rises on hepatitis/HIV drug pact
	AP (Wed, Feb 3)

•	Achillion shares rise on drug development deal in China
	at Reuters (Tue, Feb 2)

•	Achillion Pharma upgraded by Wedbush Morgan
	Briefing.com (Tue, Feb 2)

•	Achillion Announces License Agreement for Elvucitabine Development in China
	GlobeNewswire (Tue, Feb 2)

More Headlines for ACHN...

ANALYST

EPS Est (next year) (Dec-09) :	-0.94
EPS Est (in 2 years) (Dec-10) :	-0.60
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•